Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

NVS

Novartis AG ADR

May 31 • 04:00PM ET

103.13

Dollar change +2.43
Percentage change 2.41	%

Healthcare • Drug Manufacturers - General • Switzerland • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	14.00	EPS (ttm)	7.37	Insider Own	0.00%	Shs Outstand	2.04B	Perf Week	2.00%
Market Cap	201.77B	Forward P/E	13.00	EPS next Y	7.93	Insider Trans	-	Shs Float	1.96B	Perf Month	5.77%
Income	15.24B	PEG	1.38	EPS next Q	1.81	Inst Own	7.26%	Short Float	0.26%	Perf Quarter	1.05%
Sales	48.66B	P/S	4.15	EPS this Y	11.95%	Inst Trans	-9.12%	Short Ratio	3.47	Perf Half Y	6.31%
Book/sh	19.44	P/B	5.30	EPS next Y	9.49%	ROA	8.86%	Short Interest	5.13M	Perf Year	13.23%
Cash/sh	4.98	P/C	20.69	EPS next 5Y	10.16%	ROE	19.96%	52W Range	88.86 - 108.78	Perf YTD	2.14%
Dividend Est.	3.67 (3.56%)	P/FCF	15.87	EPS past 5Y	5.63%	ROI	26.11%	52W High	-5.19%	Beta	0.58
Dividend TTM	3.74 (3.63%)	Quick Ratio	0.71	Sales past 5Y	0.78%	Gross Margin	72.13%	52W Low	16.05%	ATR (14)	1.19
Dividend Ex-Date	Mar 07, 2024	Current Ratio	0.90	EPS Y/Y TTM	126.83%	Oper. Margin	27.40%	RSI (14)	63.96	Volatility	0.86% 0.71%
Employees	76057	Debt/Eq	0.69	Sales Y/Y TTM	-4.53%	Profit Margin	31.33%	Recom	2.52	Target Price	110.35
Option/Short	Yes / Yes	LT Debt/Eq	0.47	EPS Q/Q	20.88%	Payout	44.73%	Rel Volume	1.34	Prev Close	100.70
Sales Surprise	3.40%	EPS Surprise	7.29%	Sales Q/Q	-8.68%	Earnings	Apr 23 BMO	Avg Volume	1.48M	Price	103.13
SMA20	2.29%	SMA50	5.54%	SMA200	4.68%	Trades		Volume	1,977,541	Change	2.41%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform
Sep-14-22	Downgrade	Berenberg	Buy → Hold
May-09-22	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-10-22	Resumed	Citigroup	Buy
Dec-14-21	Downgrade	Redburn	Buy → Neutral
Dec-06-21	Downgrade	Exane BNP Paribas	Outperform → Neutral
Dec-03-21	Downgrade	Bryan Garnier	Buy → Neutral
Sep-20-21	Downgrade	Deutsche Bank	Hold → Sell
Mar-22-21	Initiated	Bernstein	Mkt Perform

Show Previous Ratings

May-31-24 01:02PM	Novartis (NVS) Reports Positive Long-Term Data on CSU Drug (Zacks)
12:38PM	Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine (CNBC TV)
12:18PM	15 Most Profitable Biotechnology Companies in the World (Insider Monkey)
08:00AM	Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML (GlobeNewswire)
06:55AM	Novartis reports Phase III data for trials of remibrutinib to treat CSU (Clinical Trials Arena)
04:00AM	Loading…
04:00AM	Novartis study points to larger role for targeted leukemia drug (BioPharma Dive)
May-30-24 06:01PM	Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria (GlobeNewswire)
May-28-24 06:50AM	Roches Sabry retires; Duchenne drug fails confirmatory test (BioPharma Dive)
04:35AM	Novartis and Clarius partner for psoriatic arthritis care in Canada (Medical Device Network)
May-27-24 12:29PM	Novartis (NVS) Presents Positive Data on Renal Drugs at ERA (Zacks)
04:25AM	Dr. Reddys and Novartis sign distribution agreement for anti-diabetes products (Pharmaceutical Technology)
04:25AM	Novartis atrasentan shows to reduce proteinuria in Phase III IgAN trial (Clinical Trials Arena)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
06:15AM	Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio (PR Newswire)
06:00AM	Novartis presents latest Phase III Fabhalta (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo (PR Newswire)
05:21PM	Loading…
May-23-24 05:21PM	Meta, T-Mobile and Disney Boosted US Dividend Growth in First Quarter (Investopedia)
May-22-24 05:17PM	Top 20 Largest Publicly Traded Healthcare Companies (Insider Monkey)
04:56AM	Latest 340B ruling delivers blow to providers (Healthcare Dive)
May-17-24 05:51AM	Erasca restructures; Novartis moves to complete MorphoSys deal (BioPharma Dive)
May-16-24 01:00PM	Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment DelveInsight (GlobeNewswire)
07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
06:15AM	Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade (InvestorPlace)
05:27AM	Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash (GlobeNewswire)
May-15-24 10:00AM	Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA (GlobeNewswire)
08:19AM	Legend Biotech Corporation (NASDAQ:LEGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-14-24 06:30AM	3 Magnificent Stocks That Are Passive Income Machines (Motley Fool)
12:20AM	Q1 2024 Legend Biotech Corp Earnings Call (Thomson Reuters StreetEvents)
May-11-24 09:46AM	The 3 Best Mutual Funds to Buy in May 2024 (InvestorPlace)
May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
May-08-24 03:15PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	Loading…
May-07-24 07:00AM	Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-24 02:25PM	2 Magnificent Dividend Stocks to Hold for the Next Decade (Motley Fool)
May-03-24 04:06PM	Bausch + Lomb Corporation (NYSE:BLCO) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:08PM	Appian Corporation (NASDAQ:APPN) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:36PM	Lantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:15AM	Why selling to Novartis made sense for Mariana (BioPharma Dive)
May-02-24 03:58PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)
01:59PM	Sector Update: Health Care Stocks Retreat Thursday Afternoon (MT Newswires)
11:54AM	Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat (MT Newswires)
10:30AM	Update: Novartis AG to Acquire Mariana Oncology in Deal Valued Up to $1.75 Billion. (MT Newswires)
08:20AM	Novartis to buy Mariana Oncology in radiopharmaceutical expansion (BioPharma Dive)
07:36AM	Novartis AG to Acquire Mariana Oncology (MT Newswires)
07:30AM	UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion (Reuters)
03:01AM	The top pharmaceutical companies by R&D expenditure (Pharmaceutical Technology)
May-01-24 09:09PM	Novartis further entrenches into radiopharma with $1B Mariana buy (FierceBiotech.com)
01:46PM	CVS stresses 'margins over membership' to offset Medicare pressure (Yahoo Finance)
01:46PM	CVS stock plunges after earnings numbers one analyst 'did not even believe' (Yahoo Finance)
11:12AM	Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:00AM	Novartis Is Tracking Well Above the Industry (GuruFocus.com)
Apr-30-24 11:50AM	Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications (MT Newswires)
07:00AM	PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis (Business Wire)
04:14AM	Novartis pays PeptiDream $180M as radiopharma big bang continues (FierceBiotech.com)
Apr-25-24 08:30AM	Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market (Investor's Business Daily)
Apr-24-24 11:42AM	Novartis bags paediatric FDA label expansion for Lutathera (Pharmaceutical Technology)
10:54AM	Novartis Says New Malaria Drug Formulation Safe and Effective for Babies (MT Newswires)
10:30AM	Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-23-24 06:25PM	Why Novartis Stock Topped the Market on Tuesday (Motley Fool)
05:05PM	FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors (Benzinga)
04:01PM	How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint (Investor's Business Daily)
03:18PM	Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children (MT Newswires)
02:38PM	Novartis CEO: Here's why we boosted our full-year guidance (CNBC TV)
01:54PM	Top Stock Movers Now: General Motors, Kimberly-Clark, PepsiCo, and More (Investopedia)
01:42PM	Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors (GlobeNewswire)
12:53PM	NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
12:34PM	Health Care Roundup: Market Talk (The Wall Street Journal)
12:24PM	Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock (MT Newswires)
12:16PM	Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb (Investopedia)
12:15PM	Analyst Report: Novartis AG (Morningstar Research)
12:07PM	Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024 (Associated Press Finance)
11:32AM	Novartis Stock Jumps After Beating Expectations, Raising Guidance (The Wall Street Journal)
11:15AM	Novartis Ag (NVS) Q1 2024 Earnings Call Transcript (Motley Fool)
10:51AM	Novartis raises full-year guidance on Q1 beat, drug sales (Yahoo Finance Video)
09:30AM	Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics (Zacks)
09:00AM	Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised (Zacks)
08:59AM	Stocks to Watch Tuesday: GM, Spotify, UPS, Tesla (The Wall Street Journal)
08:52AM	Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise (Investor's Business Daily)
07:45AM	Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated (MT Newswires)
07:29AM	Stocks to Watch Tuesday: UPS, Spotify, GM, Tesla (The Wall Street Journal)
05:15AM	Stocks to Watch Tuesday: Tesla, Tapestry, Cadence Design Systems (The Wall Street Journal)
05:02AM	Novartis: Q1 Earnings Snapshot (Associated Press Finance)
04:58AM	UPDATE 1-Healthcare, tech stocks boost STOXX 600 to one-week high (Reuters)
04:31AM	Novartis Q1 Profit Tops Market, Lifts FY24 View, Proposes New Chair; Stock Up (RTT News)
04:08AM	Novartis Raises Guidance on Profit, Sales Growth (The Wall Street Journal)
03:01AM	Techs boost STOXX to one-week high; euro zone data on tap (Reuters)
01:18AM	UPDATE 4-Novartis raises guidance after beating Q1 expectations (Reuters)
01:00AM	Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised (GlobeNewswire)
Apr-22-24 06:08PM	25 Richest Billionaires in Healthcare Industry (Insider Monkey)
Apr-19-24 10:10AM	Novartis (NVS) to Report Q1 Earnings: What to Expect? (Zacks)
Apr-18-24 06:33PM	US FDA mandates label updates on CAR-T cancer therapies (Reuters)
09:15AM	Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-17-24 09:30AM	2 High-Yield Dividend Stocks to Buy and Hold for 10 Years (Motley Fool)
01:15AM	Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis (GlobeNewswire)
Apr-16-24 09:06AM	Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug (Zacks)
Apr-15-24 02:00PM	New Novartis Fabhalta (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) (PR Newswire)
04:46AM	Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining. (Yahoo Finance)
Apr-12-24 01:55PM	Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate (Zacks)
08:53AM	NICE recommends Novartis' CAR-T therapy for leukaemia (Pharmaceutical Business Review)
06:26AM	Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing (FierceBiotech.com)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
11:27AM	Novartis wants to buy a German cancer drugmaker as it stops recruiting for its own trials (Quartz)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVS

Novartis AG ADR

Upgrade your FINVIZ experience